Grant: Engage Grants Program
University of Manitoba
$25,000.00
Imaging of antibody therapeutics in mouse models of Alzheimer's Disease
FY 2014-15
Summary
Alzheimer's Disease (AD) is the most common cause of dementia, leading to debilitating memory loss and ultimately death. A hallmark of the disease is the accumulation of amyloid beta plaques in the brain, leading to neurofibrillary tangles and decreased synaptic density. It is thought that preventing the accumulation of amyloid beta in the brain is necessary to prevent the development of amyloid plaques and therefore avoid the degradation in neurological function that these plaques cause. Cangene is a Winnipeg-based biotechnology company that has developed antibody agents that can bind to amyloid beta when injected into the mouse or rat brain. A key challenge to the further development of these therapeutic agents is an understanding of how much of the antibody crosses the blood brain barrier (BBB) and thus has the ability to bind amyloid beta in the brain. In this NSERC Engage project, researchers at the University of Manitoba, in collaboration with Cangene, will label the newly developed antibodies with both fluorescent and radioactive dyes and then measure their uptake in the brain following systemic injection using non-invasive fluorescence and positron emission tomography (PET) imaging in mouse models of AD. The outcome of this project will be the development of new imaging protocols and analysis techniques that enable cross-modality quantification of antibody uptake in the mouse brain. These cross-platform quantification methods will allow Cangene to use these in vivo imaging methods in the future for rapid evaluation of new antibody isotypes, reducing the time required for identification of promising new therapeutic agents.
Program
Engage Grants Program
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
462641-2014
Name nom
Goertzen, Andrew
Department département
Radiology
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Imaging of antibody therapeutics in mouse models of Alzheimer's Disease
Keyword
NSERC
Application summary
Alzheimer's Disease (AD) is the most common cause of dementia, leading to debilitating memory loss and ultimately death. A hallmark of the disease is the accumulation of amyloid beta plaques in the brain, leading to neurofibrillary tangles and decreased synaptic density. It is thought that preventing the accumulation of amyloid beta in the brain is necessary to prevent the development of amyloid plaques and therefore avoid the degradation in neurological function that these plaques cause. Cangene is a Winnipeg-based biotechnology company that has developed antibody agents that can bind to amyloid beta when injected into the mouse or rat brain. A key challenge to the further development of these therapeutic agents is an understanding of how much of the antibody crosses the blood brain barrier (BBB) and thus has the ability to bind amyloid beta in the brain. In this NSERC Engage project, researchers at the University of Manitoba, in collaboration with Cangene, will label the newly developed antibodies with both fluorescent and radioactive dyes and then measure their uptake in the brain following systemic injection using non-invasive fluorescence and positron emission tomography (PET) imaging in mouse models of AD. The outcome of this project will be the development of new imaging protocols and analysis techniques that enable cross-modality quantification of antibody uptake in the mouse brain. These cross-platform quantification methods will allow Cangene to use these in vivo imaging methods in the future for rapid evaluation of new antibody isotypes, reducing the time required for identification of promising new therapeutic agents.